Medications for Coronary Artery Disease: Complete Drug Class Guide

Coronary artery disease (CAD) management requires a multi-drug approach targeting atherosclerosis progression, thrombosis prevention, symptom control, and risk factor modification. Contemporary guidelines (ACC/AHA/ESC) emphasize evidence-based combination therapy.

1. Antiplatelet Therapy (Thrombosis Prevention)

DAPT duration: 12 months post-ACS/PCI (shorter if high bleeding risk; longer if high ischemic risk)

2. Statins (Lipid Lowering / Plaque Stabilization)

  • High-intensity: Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg → ≥50% LDL reduction
  • Moderate-intensity: Atorvastatin 10-20, Rosuvastatin 5-10, Simvastatin 20-40 → 30-49% LDL reduction
  • Goal: LDL <70 mg/dL (very high risk) or <55 mg/dL (extreme risk per ESC)
  • Pleiotropic effects: Anti-inflammatory, plaque stabilization, endothelial improvement
  • Add-ons: Ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab), bempedoic acid if not at goal

3. Blood Pressure Control

ACE Inhibitors

  • Lisinopril, ramipril, enalapril, perindopril
  • Indications: CAD + HTN, diabetes, CKD, HFrEF, post-MI
  • Benefits: Reduce mortality, MI, stroke; regress LVH
  • Monitor: K⁺, creatinine, cough, angioedema

ARBs (ACEi Alternative)

  • Losartan, valsartan, candesartan, olmesartan
  • Similar indications; no cough; less angioedema
  • Valsartan/sacubitril (ARNI) for HFrEF

Beta-Blockers

  • Metoprolol succinate, carvedilol, bisoprolol, nebivolol
  • Mortality benefit: Post-MI, HFrEF, hypertension
  • Mechanism: ↓HR, ↓contractility, ↓O₂ demand, antiarrhythmic
  • Post-MI: Initiate early; continue indefinitely

Calcium Channel Blockers

  • Dihydropyridines: Amlodipine (vasoselective) — HTN, vasospastic angina
  • Non-DHP: Verapamil, diltiazem — rate control, HTN (avoid in HFrEF)

Mineralocorticoid Receptor Antagonists

  • Spironolactone, eplerenone — HFrEF, resistant HTN

4. Antianginal Therapy (Symptom Control)

  • Nitrates: Sublingual (acute), long-acting (isosorbide mononitrate), patches — venodilation ↓preload, coronary dilation
  • Ranolazine: Late Na⁺ current inhibition — improves diastolic function; no HR/BP effect
  • Ivabradine: If sinus rhythm, HR ≥70 on max beta-blocker — HFrEF, chronic angina
  • Trimetazidine: Metabolic modulator (shifts to glucose oxidation)

5. Emerging / Adjunctive Therapies

  • SGLT2 inhibitors (empagliflozin, dapagliflozin): CV death/HF hospitalization reduction in T2D + CAD; now indicated for HF regardless of DM
  • GLP-1 RAs (semaglutide): MACE reduction in T2D + ASCVD
  • Colchicine 0.5 mg: Anti-inflammatory; reduces recurrent events post-MI
  • Omega-3 (icosapent ethyl 4g): High-risk TG 135-499 on statin

Treatment Algorithm Summary

  1. All CAD: Aspirin + high-intensity statin + lifestyle
  2. Post-MI/ACS: Add beta-blocker, ACEi/ARB, P2Y₁₂ inhibitor (DAPT)
  3. HFrEF: GDMT quad: ACEi/ARB/ARNI + beta-blocker + MRA + SGLT2i
  4. Angina: Add antianginals stepwise
  5. Risk factors: Treat to target (BP, LDL, glucose, weight, smoking)

Monitoring and Adherence

  • Regular follow-up: lipids, renal function, LFTs, glucose, side effects
  • Deprescribing when appropriate (e.g., DAPT completion)
  • Shared decision-making for elderly/frail (polypharmacy, fall risk)

Key principle: CAD medication is not "one size fits all." Regimen intensity matches ischemic/bleeding risk, comorbidities, and patient preferences. Regular reassessment ensures optimal benefit-risk balance.

Cardiovascular Disease - Related Articles

Health Sciences © https://www.222health.com

DrugMechanismIndicationKey Points
Aspirin 81 mgCOX-1 inhibition → ↓TXA₂All CAD (primary/secondary prevention)Lifelong unless contraindicated; GI bleeding risk
ClopidogrelP2Y₁₂ inhibitionACS, PCI/stent, aspirin intoleranceCYP2C19 loss-of-function alleles reduce efficacy
TicagrelorReversible P2Y₁₂ inhibitionACS, post-MIFaster onset/offset; dyspnea side effect; BID dosing
PrasugrelIrreversible P2Y₁₂ inhibitionACS with PCIContraindicated if prior stroke/TIA; bleeding risk